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Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416A168Western Ontario and McMaster Universities Arthritis Index (WOMAC),
function by Lequesne Algofunctional Index, mobility by Timed Up and
Go Test (TUG), KROM by goniometry of knee ﬂexion and hamstring
shortening by popliteal angle. The statistical method followed the
principles of per-protocol analysis.
Results: On average, the participants’ age was 63.5 years, the BMI was
31.2 and 78.4% were women. All groups demonstrated a signiﬁcant
improvement in pain, total WOMAC, Lequesne and TUG following
treatment compared to control (both p<.001). Hamstring shortening
improved after the combined treatment (LLLT þ stretching) (p<.001).
The LLLTPLACEBO þ Stretch was the only group better than control in
improving KROM (p¼0.02). On average, there was a 50% improve-
ment in pain, 39% in total WOMAC, 30% in Lequesne and 20% in TUG
for all active treatment groups compared to a control. For the com-
bined treatment groups there was a 43% improvement in hamstring
length.
Conclusions: Our results suggest that LLLT and static stretching, com-
bined or as monotherapy, were effective in reducing pain and improv-
ing self-reported symptoms, mobility and function. Only the combined
treatment demonstrated improvements in hamstring shortening.Initial Assessment x Final Assessment
Groups Average gain Relative
gain
p
Average ± SD/ Median
[25%-75%]
VAS (0e10 cm) 1 3.2 ± 2.1 50.3% <0.001
2 3.8 ± 2.3 57.7%
3 3.1 ± 2.9 47.0%
4 3.3 ± 2.2 54.2%
5 0.7 ± 3.0 12.4%
WOMAC (0e96) 1 8.0 [6.0  15.0] 33.9% <0.001
2 11.0 [4.5  21.5] 38.9%
3 13.0 [5.7  22.5] 42.0%
4 16.0 [8.7  24.5] 41.4%
5 2.0 [ 2.5  8.5] 1.5%
LEQUESNE (0e24) 1 2.5 [0.4  5.1] 23.4% <0.001
2 1.5 [0.5  5.2] 25.8%
3 4.0 [0.5  6.6] 39.6%
4 3.5 [1.9  5.6] 31.5%
5 0.0 [2.2  1.0] -10.4%
TUG(s) 1 2.5 [0.2  4.7] 18.0% <0.001
2 3.0 [1.1  6.7] 23.1%
3 2.6 [1.3  4.1] 19.1%
4 3.1 [0.5  6.4] 19.9%
5 0.0 [1.0  1.2] -1.3%
KROM () 1 7.0 [3.0  15.0] 9.4% 0.02
2 10.0 [4.0  15.2] 12.0%
3 6.0 [1.0  11.5] 5.3%
4 10.0 [7.5  23.2] 8.5%
5 1.0 [5.5  7.0] 0.9%
Popliteal angle () 1 10.0 [1.0  15.0] 37.6% <0.001
2 12.0 [5.0  18.2] 47.9%
3 4.0 [1.2  8.7] 11.7%
4 0.0 [6.0  6.2] 1.2%
5 0.5 [4.5  4.0] 1.2%255
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Purpose: Nerve Growth Factor (NGF) is a neurotrophin that regulates
the structure and function of responsive sensory neurons and is a
regulator of pain sensitivity and processing. The concept of targeting
NGF to target chronic pain syndromes has been gaining momentum
since 1990.
There have been a signiﬁcant number of trials conducted or being ini-
tiated. This abstract provides a review of the studies that have evaluated
a-NGF compounds.Methods: A thorough review was performed on the web site www.
clinicaltrials.gov to identify all a-NGF studies that have been con-
ducted. The terms anti-NGF, and a-NGF only return a limited number
of results so the individual compounds had to be identiﬁed either by
their generic name or compound number. 45 studies were identiﬁed
and although 2 studies had been withdrawn prior to randomization, a
total of 15,664 subjects have been enrolled in studies with the aNGF
mAbs. Seven of these trials have been published in peer-reviewed
journals.
Results: While the majority (26) of studies have been conducted by
Pﬁzer with Tanezumab, there have been 7 with Fulranumab previously
known as JNJ-42160443 (Johnson & Johnson Pharmaceutical Research
& Development), and 9 with Fasinumab previously known as REGN475
(Regeneron pharmaceuticals/Sanoﬁ). Many of the studies have been
either terminated (24), or completed (16) but there is one currently
active (not recruiting) in cancer-related pain (Fulranumab). There is also
a study of 450 subjects with OA of the knee and hips that is planned to
start recruiting in January 2014.
The number of indications that have been studied comprise of osteo-
arthritis (21), which includes either the knee, hip or both; low back pain
(4), and a variety of pain syndromes (11) including neuropathic pain
from diabetes (2), plus three in cancer pain of which one is on-going.
In the Tanezumab program 249 subjects were adjudicated for AEs
related to the joints. Of these 68 had Rapidly Progressing Osteoarthritis
(RPOA), 67 in the Phase III program and 1 in the Phase 1 program for
chronic back pain. The advisory board noted that 13 of the 68 subjects
had deﬁnite evidence of SIF at enrollment. This program had the largest
number of enrolled subjects at the time of FDA cessation of the program
(13310 subjects of the 15,664 enrolled in aNGF studies or 85%). While
these subjects were identiﬁed post hoc, SIF, RPOA and joint destruction
was not an AE that was anticipated a priori and therefore nothing pro-
actively built into the studies to evaluate the true incidence of these
events.
Conclusions: In summary, medical imaging and the thorough radio-
logical evaluation of the major articulating joints for all subjects in
future aNGF studies will be required. The ﬁrst step will be to rule out
possible pathology or those at high risk of going onto a catastrophic
joint failure. Then secondly to closely monitor the subjects during the
treatment phase with radiography and if inconclusive also with mag-
netic resonance imaging to ensure that any possible events will be
identiﬁed early and the subject managed to prevent any further bone or
joint damage.
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Purpose: The osteoarthritis (OA) research community has long-stand-
ing experience with studies assessing therapeutic efﬁcacy, which is
commonly deﬁned as slowing of joint space narrowing (JSN). Para-
mount for longitudinal radiologic evaluation of radiographs is opti-
mized image acquisition in a reliable fashion in order to guarantee
comparability between time points. Recently nerve growth factor
inhibitors (a-NGF) have been introduced for treatment of OA symptoms,
and have shown good analgesic efﬁcacy and improvement in function
in patients with OA. However, a-NGF trials in OAwere suspended due to
concerns over accelerated rates of OA progression. Since a-NGF thera-
pies offer potential as the ﬁrst new class of analgesics in many years,
future studies assessing a-NGF compounds will include stringent eli-
gibility criteria as risk mitigation measures and will require rigorous
safety monitoring during the studies. While disease-modifying effects
are not expected with a-NGF treatment, imaging is paramount to
identify potential negative outcomes as early as possible. These imaging
ﬁndings include atrophic OA, osteonecrosis and others at screening and
especially rapidly progressive OA Type I (i.e. rapid progression of JSN
>2mm/year) and II (i.e. abnormal loss of bone or bone destruction that
